U.S. Small Molecule Innovator Api Cdmo Market Size & Outlook
U.S. small molecule innovator api cdmo, 2018-2030 (US$M)
Related Markets
U.S. small molecule innovator api cdmo highlights
- The U.S. small molecule innovator api cdmo generated a revenue of USD 8,200.5 million in 2023 and is expected to reach USD 12,604.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
- In terms of segment, clinical was the largest revenue generating stage type in 2023.
- Commercial is the most lucrative stage type segment registering the fastest growth during the forecast period.
Small molecule innovator api cdmo data book summary
| Market revenue in 2023 | USD 8,200.5 million |
| Market revenue in 2030 | USD 12,604.4 million |
| Growth rate | 6.3% (CAGR from 2023 to 2030) |
| Largest segment | Clinical |
| Fastest growing segment | Commercial |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Preclinical, Commercial, Clinical |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, Siegfried Holding AG, Recipharm, CordenPharma, Samsung BioLogics, Labcorp Holdings Inc, Ajinomoto Co Inc, Piramal Pharma Solutions, Jubilant Biosys, Wuxi AppTec Co Ltd |
Other key industry trends
- In terms of revenue, U.S. accounted for 27.4% of the global small molecule innovator api cdmo in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. small molecule innovator api cdmo is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 12,604.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Small Molecule Innovator API CDMO Scope
Small Molecule Innovator API CDMO Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. small molecule innovator api cdmo outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator api cdmo will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 54.8% in 2023. Horizon Databook has segmented the U.S. small molecule innovator api cdmo based on preclinical, commercial, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Small Molecule Innovator API CDMO Stage Type Outlook (Revenue, USD Million, 2018-2030)
- Preclinical
- Commercial
- Clinical
- Phase I
- Phase II
- Phase III
- U.S. Small Molecule Innovator API CDMO Customer Type Outlook (Revenue, USD Million, 2018-2030)
- Pharmaceutical
- Small
- Medium
- Large
- Biotechnology
- Small
- Medium
- Large
- Pharmaceutical
- U.S. Small Molecule Innovator API CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Cardiovascular diseases
- Oncology
- Respiratory disorders
- Neurology
- Metabolic Disorders
- Infectious Diseases
- Others
Reasons to subscribe to U.S. small molecule innovator api cdmo databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. small molecule innovator api cdmo databook
-
Our clientele includes a mix of small molecule innovator api cdmo companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. small molecule innovator api cdmo, including forecasts for subscribers. This country databook contains high-level insights into U.S. small molecule innovator api cdmo from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. small molecule innovator api cdmo market report size, by stage type, 2018-2030 (US$M)
U.S. Small Molecule Innovator API CDMO Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
